

Methylprednisolone Sodium Succinate

【ISOLM】Medason® 40mg/Vial

ATC Code : H02AB04

中文名：命得生注射劑 «南光»

【ISOL5】500mg Solu-Medrol® 500mg/Vial

ATC Code : H02AB04

中文名：舒汝美卓佑注射劑 «輝瑞»

適應症：腎上腺皮質機能不全、劇烈休克、支氣管性氣喘、膠原疾病、過敏反應、泛發性感染。

藥理分類：Corticosteroid, Systemic.

用法用量：**Administration : IV, rate dependent upon dose and severity of condition.**

1. typically, intermittent infusion is administered over **15 to 60 minutes**.

2. administer large doses over at least **30 to 60 minutes**; do not administer large doses as IV push.

3. IV infusion over at least 30 minutes (manufacturer label).

Usual dosage:

When the drug is administered by direct IV injection, administer over a period of several minutes.

—Adults:

Usually, 10-250 mg IV or IM; may repeat up to 6 times daily.

—Children:

0.03-0.2 mg/kg or 1-6.25 mg/m² IM, 1-2 times daily.

Life-threatening Shock:

- 30 mg/kg by direct IV injection (over 3-15 min) initially and repeated in 4-6 hours if needed OR 100-250 mg by direct IV injection (over 3-15 min) initially and repeated at 2- to 6- hour intervals as required.
- Alternatively, following the initial dose by direct IV injection, additional dose of 30 mg/kg may be administered by slow continuous IV infusion every 12 hours for 24-48 hour.

不良反應：腸胃不適，情緒變化，食欲增加，水腫，視力模糊，骨質疏鬆，毛髮增加等。

交互作用：methylprednisolone = MTP

- **Desmopressin**: MTP ↑ the hyponatremic effect of Desmopressin.
- **Mifepristone**: ↓ the therapeutic effect of Corticosteroids (Systemic).
- **Aprepitant, Fosaprepitant**: ↑ the serum concentration of MTP.
- Corticosteroids (Systemic) may ↓ the therapeutic effect of COVID-19 Vaccine.
- CYP3A4 Inducers (Carbamazepine, Phenytoin, Rifampin) : ↓ the serum concentration of MTP.
- Leflunomide: MTP may ↑ the immunosuppressive effect of Leflunomide.
- Live Vaccines: MTP may ↑ the adverse/toxic effect of Vaccines (Live).

懷孕期：

1. Methylprednisolone crosses the placenta (*Anderson 1981*).
2. Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts or decreased birth weight; however, information is conflicting. (*Lunghi 2010; Park-Wyllie 2000; Pradat 2003*).
3. Due to risks of adverse fetal events associated with first trimester exposure, use is reserved for refractory cases in women with dehydration (*ACOG 189 2018*).
4. 只應在經過謹慎評估對母體和胎兒的益處/風險比後，才可於孕婦使用這項醫療產品。(仿單)

- 授乳期： 1.皮質類固醇會於乳汁中分泌。
2.分佈在乳汁中的皮質類固醇，可能嬰兒的生長受到抑制，並干擾內生性糖皮質素的生成。由於目前尚未對人類以糖皮質素進行過適當的生殖研究，因此，在考量對授乳婦的治療效益下，須在停止授乳或停止用藥間做一選擇。
- 安定性： 調製後的溶液(reconstituted solution)進一步稀釋後用於輸注時：稀釋後的溶液若存放於 20-25°C，須於 3 小時內使用，若存放於 2-8°C，須於 24 小時內使用。
- 輸液相容性： 1.Compatible: D5W-1/2NS, D5NS, NS
2.Variable (compatibility concentration dependent): D5W, Lactated Ringer's